Gilad&Gilad LLC, a USA company, is proud to announce that the abstract entitled "Efficacy of Dietary Agmatine Sulfate in Herniated Lumbar Disc-Associated Radiculopathy. A Randomized, Double-Blind, Placebo-Controlled Study" was chosen by the American Academy of Neurology for the Highlights session in the Field of Spine held on Tuesday, April 13, 2010, during the 62nd meeting of the Academy in Toronto, Canada.
The clinical studies demonstrated the safety profile of G-agmatineTM, Gilad&Gilad's brand of agmatine, and its efficacy in people suffering from sciatica due to herniated lumbar disc. The random, placebo-controlled trial was conducted in a double-blind fashion and showed a significant accelerated improvement of neuropathic pain and health-related quality of life in those who took G-agmatineTM for 14 days (31 people), as compared to the placebo group (30 people).
The study was led by neuroscientists Gad Gilad and Varda Gilad and performed by orthopedic surgeons Ory Keynan and Yigal Mirovsky of Tel Aviv University, Faculty of Medicine and was conducted at the Tel-Aviv Sourasky Medical Center and Assaf Harofeh Medical Center (Israel Ministry of Health National Review Board Trial Number: 20060409). and registered with ClinicalTrials.gov Protocol Registration System (ClinicalTrials.gov Identifier: NCT00405041).
It is estimated that more than 20 million people in the United States alone suffer from neuropathy of various causes for whom effective medication is still lacking. The present findings, therefore, have wide implications for millions of people worldwide.
About Gilad&Gilad LLC
Gilad&Gilad is a privately owned company in Reseda, California, with a mission to providing safe and effective products of the highest quality for healthier nervous system function and pain-free quality of life. It was founded in 2000 by Dr. Gad Gilad and his wife Varda Gilad following 30 years of collaborative scientific research and based on their breakthrough discovery of the neuroprotective properties of G-agmatineTM.